News | Stents Bifurcation | October 14, 2015

Tryton Side Branch Stent Meets Primary Endpoint in Pivotal Confirmatory Study

Positive results presented at Transcatheter Cardiovascular Therapeutics symposium support planned PMA submission

Tryton Confirmatory Study, Side Branch Stent, TCT 2015, bifurcation lesions

Image courtesy of Tryton Medical

October 14, 2015 — Tryton Medical Inc. announced results from the pivotal Tryton Confirmatory Study confirming the acceptable acute safety profile of the Tryton Side Branch Stent for the treatment of coronary bifurcation lesions in vessels appropriate for a ≥2.5mm stent. Results were presented as part of the Featured Clinical Research session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) being held in San Francisco, California.

The Tryton Confirmatory Study (single-arm clinical trial, n=133) was designed to validate the acute safety profile of the Tryton Side Branch Stent shown in a post hoc analysis of the Tryton Randomized Clinical Trial (RCT, n=704). The post hoc analysis of the Tryton RCT showed the device reduced target vessel failure and improved side branch percent diameter stenosis when compared with provisional stenting in the intended treatment population (appropriate for a ≥2.5mm stent). The Tryton Confirmatory Study showed a periprocedural myocardial infarction (PPMI) rate (primary endpoint) meeting the pre-established performance goal, set based on the PPMI rate of the provisional control arm observed in the Tryton RCT.

Results from the post hoc analysis of the Tryton RCT and the data from the Tryton Confirmatory Study will be used to support Tryton’s Premarket Approval (PMA) application for Tryton Side Branch Stent to the U.S. Food and Drug Administration in the coming weeks.

“These findings provide strong clinical evidence demonstrating that the Tryton Side Branch Stent provides predictability and durability when treating coronary bifurcation lesions with significant side branches, while preserving main vessel results,” said principal investigator Dr. Martin B. Leon, director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, New York-Presbyterian Hospital. “With an established safety profile, Tryton has the potential to disrupt standard strategies for treating complex bifurcation lesions.”

The Tryton Side Branch Stent System is built using proprietary Tri-Zone technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

The device is commercially available in multiple countries within Europe, Middle East & Africa, is investigational in the United States and is not available in Japan.

For more information: www.trytonmedical.com

Related Content

Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.